Abstract
The 21st century has brought forth major advancements in device-based treatments for psychiatric disorders such as major depressive disorder (MDD). One of the most exciting technologies on the rise in this field is transcranial alternating current stimulation (tACS). The small but rapidly growing body of knowledge on tACS suggests that this wearable, low-cost, noninvasive neuromodulation method could provide a safe and effective alternative, or augmentation, to pharmacological interventions for MDD. While device parameters for treatment of MDD need refinement before this method is ready for standardized clinical use, we expect that tACS will make a significant impact on psychiatric treatment in the coming years. [ Psychiatr Ann . 2022;52(11):456–460.]
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
